Research & Development
BioFluidica to commercialise LiquidScan Automated Liquid Biopsy System
20 September 2021 -

BioFluidica, a US-based privately held biotechnology company, announced on Friday that it planning to commercialise the LiquidScan Automated Liquid Biopsy System, a high throughput rare biomarker (circulating tumour cells, exosomes, and cell-free DNA) enrichment solution.

The company has designed and developed an automation-ready liquid biopsy instrument compatible with Hamilton Robotics Microlab STAR series liquid handlers. The commercial version of the LiquidScan system is produced under present Good Manufacturing Practices and includes complete documentation to facilitate clinical application development and clinical trials under EUA and FDA guidelines.

BioFluidica is offering a limited number of systems to certain Core facilities in North America through Early Technology Access Program from fourth quarter of 2021.

Login
Username:

Password:


Related Headlines

Dr. Reddy's Laboratories unveils Carmustine for Injection, USP in the US Market

FDA Approves Merck's Keytruda Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients with Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)

Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer

FDA Approves Merck's Keytruda Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients with Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin's Lymphoma

Sobi and Apellis report positive opinion by EMA committee

Detect to accelerate manufacturing of PCR-Quality Rapid At-Home Covid-19 Test under NIH RADxSM initiative and President Biden's Covid-19 Action Plan

Moderna expects the FDA advisory committee to support emergency use of booster COVID-19 Vaccine dose in the US

Cantargia receives positive EMA opinion for orphan designation of nadunolimab in pancreatic cancer

Eli Lilly's Verzenio(R) (abemaciclib) and endocrine therapy combination gains US FDA breast cancer treatment approval

Novartis's Beovu(R) receives FDA and EMA filing acceptances for patients with diabetic macular edema

Eli Lilly wins FDA approval of Verzenio for treatment of HR+ HER2- high risk early breast cancer

Kiromic BioPharma Forges Strategic Collaboration with Gemelli Teaching Hospital to Accelerate the Analysis of Allogeneic CAR-T Clinical Trial Candidate Alexis ISO-1 in Solid Cancers

Revance confident of FDA approval of DaxibotulinumtoxinA for Injection

US FDA scientists state Moderna does not meet all criteria for COVID-19 boosters